72% and Falling: WTO Says the Rules-Based Trading System Is Eroding

72% and Falling: WTO Says the Rules-Based Trading System Is Eroding — and the Price Tag Is 10% of Global GDP

Nine days ago in Geneva, the World Trade Organization released a report that did not mince words. "Global trade policy and the WTO are experiencing the most serious and sustained disruptions since the multilateral trading system was created 80 years ago," the body wrote in its flagship World Trade Report 2026, published September 15. The headline number: if cooperation breaks down and the system fractures into competing blocs or a patchwork of bilateral deals, global GDP could land as much as 10 percent lower by 2050 than under a strengthened multilateral framework. That is not a forecast — it is the measured distance between two paths, and the WTO is telling its 166 members the window to choose is narrowing.

The report's diagnostic indicator is the most-favoured-nation (MFN) share — the percentage of global merchandise trade conducted on equal, non-discriminatory tariff terms. That figure stood at roughly 80 percent in 2022. By early 2026, it had fallen to 72 percent. An eight-point drop in four years is the statistical fingerprint of a system being rewired: preferential deals, targeted tariff actions, and trade-remedy measures are taking a larger share of commerce each year, eroding the non-discrimination principle that has underpinned world trade since 1947.

Three Scenarios, One Choice: What the WTO Models Show

The report does not predict the future. It models three counterfactuals to 2050 and lets the numbers argue. In the first, members deepen cooperation — broader market-opening, new rules for digital trade and services, wider membership. Global GDP rises 2.9 percent and exports climb 17.9 percent. In the second, the world splits into geopolitical blocs. GDP falls 5.1 percent and exports drop 18.6 percent. In the third, the WTO effectively ceases to function and is replaced by a web of bilateral FTAs. GDP falls 6.9 percent and exports collapse by nearly 27 percent. The spread between the best and worst cases approaches 10 percent of global real GDP — roughly US$3 trillion in annual output by mid-century.

The distributional math is sharper than the averages. Least-developed countries, which account for less than 1 percent of global trade despite decades of expansion, could lose as much as 16.5 percent of GDP under the FTA-world scenario — more than three times the projected losses for high-income economies. The MFN principle is the practical shield for smaller exporters: non-discrimination means a small country faces the same tariff terms as a large one. As commerce migrates into exclusive arrangements, non-members face both higher duties and reduced bargaining power.

Five Days to Pharma Tariff Day: The Fragmentation Made Real

The WTO's warning is abstract by design — long-run scenarios to 2050. But the fragmentation it describes has a concrete deadline arriving in five days. On September 29, 2026, at 12:01 a.m. Eastern time, the United States will begin collecting a 100 percent ad valorem tariff on imported patented pharmaceuticals and their active ingredients from every company not already covered by the first wave. The duty stems from Proclamation 11020, signed April 2 under Section 232 of the Trade Expansion Act of 1962, after a Commerce Department investigation concluded that pharmaceutical imports — 53 percent of patented drugs sold domestically are produced overseas, and only 15 percent of active ingredients are made in the US — threaten national security.

The tariff is tiered, not flat. Companies with a Commerce-approved onshoring plan pay 20 percent instead of 100 percent. Companies that also sign a most-favoured-nation pricing agreement with the Department of Health and Human Services pay zero through January 2029. Products from the EU, Japan, South Korea, and Switzerland face 15 percent under existing trade deals; the UK pays zero under a bilateral pharmaceutical pricing agreement. Generic drugs and biosimilars — about 90 percent of US prescriptions by volume — are exempt for now. But for patented, brand-name drugs from companies without negotiated relief, the landed cost doubles overnight.

Seventeen of the largest drugmakers — including Pfizer, Johnson & Johnson, Merck, Eli Lilly, AbbVie, Amgen, AstraZeneca, Novartis and Sanofi — have been paying the duty since July 31. September 29 extends the regime to every remaining importer: mid-sized branded drugmakers, licensees, and contract importers that lacked the scale or leverage to negotiate an onshoring agreement before the June 12 application window closed. For those companies, the landed cost on a patented drug from a non-treaty origin can double on entry date — not ship date, but customs entry date. Industry analysts have flagged Pfizer, J&J and GSK as still without confirmed Commerce onshoring agreements, a gap that could expose hospital systems and wholesalers sourcing from those manufacturers to the full 100 percent rate.

Four Forces Breaking the System — and Who Gets Hit First

The WTO report identifies four structural pressures driving the erosion. First, economic power has dispersed: low- and middle-income economies now account for 45 percent of global merchandise trade, nearly double their 23 percent share in 1995, and the old bargain no longer reflects the new balance. Second, government intervention — subsidies, industrial policy, export controls — has expanded, creating disputes over competition and the level playing field that existing rules were not designed to resolve. Third, trade itself has changed: global value chains, digital commerce and AI have generated cross-border spillovers the 1990s framework never anticipated. Fourth, geopolitical tension is straining the balance between interdependence and security, pushing governments to reassess supply-chain dependence and technology transfers.

The WTO's chief economist, Robert Staiger, called the 72 percent MFN figure a "worrisome trend" and warned that new tariffs and trade restrictions now cover 11 percent of global imports — the highest coverage in over 15 years. He also cautioned that the strength of recent trade figures may be partly artificial, propped up by an AI-related investment boom in a narrow set of countries and products rather than broad-based growth.

The pharma tariff is a case study in how these forces converge. A national security statute from 1962 is being used to restructure a global pharmaceutical supply chain, extracting manufacturing investment and price concessions in exchange for tariff relief — exactly the kind of unilateral, power-based arrangement the WTO says its rules were built to prevent. The 17 Annex III companies were named individually for different effective dates, an approach trade lawyers describe as unusual for Section 232, which typically applies uniformly by product and country. The result is a tariff regime in which the rate a company pays depends less on what it imports and more on what it has negotiated with Washington.

What Trade Operators Should Do Now

The WTO will release its updated global trade forecast on October 8. Director-General Ngozi Okonjo-Iweala has said members "recognize that the status quo is not an option" and that the system "has been repaired and renewed before." Whether that renewal arrives through negotiation or is forced by the mounting costs of fragmentation is the question that September 29 — and every tariff deadline after it — will help answer.